Stanley H. Appel, MD, Peggy & Gary Edwards Distinguished Endowed Chair, Stanley H. Appel Department of Neurology, will lead a multidisciplinary team of researchers dedicated to expanding cell therapy research at Houston Methodist. His regulatory T cell therapy for amyotrophic lateral sclerosis, or ALS, is demonstrating promising results in slowing disease progression in some patients. Appel’s cell therapy for ALS will be manufactured onsite as part of the cell therapy program at the Ann Kimball and John W. Johnson Center for Cellular Therapeutics.

will build a research program and production facility at Houston Methodist that allows us to design new therapies rapidly and produce experimental therapeutics on site. The 5,000 sq. ft. state-of-the-art Current Good Manufacturing Practice (cGMP) facility is located in the Houston Methodist Outpatient Center and opens in 2020.